Lv2
120 积分 2024-06-13 加入
De novo engineered disulfide bond supersedes native interchain linkage to enhance TCR pairing and anti-tumor efficacy in T cell therapy
26天前
已完结
Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
4个月前
已完结
Tumor organoids targeted by receptor-engineered immune cells: A promising approach for advancing cancer immunotherapy
6个月前
已完结
HBV antigen as a tumour antigen in adoptive TCR-T cell therapy for HBV-related HCC: rationale and clinical effectiveness
6个月前
已完结
皖公网安备34019202002308
